138 related articles for article (PubMed ID: 8597272)
1. Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate.
Hemady RK; Sinibaldi VJ; Eisenberger MA
Am J Ophthalmol; 1996 Mar; 121(3):291-6. PubMed ID: 8597272
[TBL] [Abstract][Full Text] [Related]
2. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
4. Suramin keratopathy.
Holland EJ; Stein CA; Palestine AG; LaRocca R; Chan CC; Kuwabara T; Myers CE; Thomas R; McAtee N; Nussenblatt RN
Am J Ophthalmol; 1988 Aug; 106(2):216-20. PubMed ID: 3400766
[TBL] [Abstract][Full Text] [Related]
5. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Dawson NA; Cooper MR; Figg WD; Headlee DJ; Thibault A; Bergan RC; Steinberg SM; Sausville EA; Myers CE; Sartor O
Cancer; 1995 Aug; 76(3):453-62. PubMed ID: 8625127
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
[TBL] [Abstract][Full Text] [Related]
8. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
Shin E; Lim DH; Han J; Nam DH; Park K; Ahn MJ; Kang WK; Lee J; Ahn JS; Lee SH; Sun JM; Jung HA; Chung TY
BMC Ophthalmol; 2020 Jan; 20(1):19. PubMed ID: 31918686
[TBL] [Abstract][Full Text] [Related]
9. [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
Wichterich K; Tebbe B; Handke A; Dieckmann KP; Gollnick H
Hautarzt; 1994 Feb; 45(2):84-7. PubMed ID: 8150636
[TBL] [Abstract][Full Text] [Related]
10. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
12. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
13. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer.
Garcia-Schürmann JM; Schulze H; Haupt G; Pastor J; Allolio B; Senge T
Urology; 1999 Mar; 53(3):535-41. PubMed ID: 10096380
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
15. Suramin-induced skin reactions.
O'Donnell BP; Dawson NA; Weiss RB; Myers CE; James WD
Arch Dermatol; 1992 Jan; 128(1):75-9. PubMed ID: 1531404
[TBL] [Abstract][Full Text] [Related]
16. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
Small EJ; Meyer M; Marshall ME; Reyno LM; Meyers FJ; Natale RB; Lenehan PF; Chen L; Slichenmyer WJ; Eisenberger M
J Clin Oncol; 2000 Apr; 18(7):1440-50. PubMed ID: 10735891
[TBL] [Abstract][Full Text] [Related]
17. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
18. Ocular Toxicity of Mirvetuximab.
Corbelli E; Miserocchi E; Marchese A; Giuffrè C; Berchicci L; Sacconi R; Bandello F; Modorati GM
Cornea; 2019 Feb; 38(2):229-232. PubMed ID: 30379722
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
[TBL] [Abstract][Full Text] [Related]
20. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
